Regeneron Pharmaceuticals Inc

REGN

Equity

ISIN null / Valor 965755

NASDAQ (2026-10-30)

USD 927.89+13.3%

Regeneron Pharmaceuticals Inc
UMushroom community rating:

4.00 1 votes No rating yet

NegativeNeutralPositive

About company

Regeneron Pharmaceuticals Inc. is a prominent biotechnology firm that specializes in the discovery, development, and commercialization of innovative medicines aimed at transforming the lives of patients suffering from serious diseases. Since its inception over three decades ago by a team of physician-scientists, the company has established a reputation for its consistent ability to convert scientific discoveries into a range of FDA-approved treatments, with a significant portion of its product portfolio being developed in-house. Regeneron focuses on addressing a variety of medical conditions, including eye diseases, allergic and inflammatory disorders, cancer, cardiovascular and metabolic issues, pain, hematologic conditions, infectious diseases, and rare diseases. The company is also known for its pioneering VelociSuite® technologies, notably VelocImmune®, which leverages genetically-engineered mice to produce fully-human antibodies, and its involvement in one of the world's most ambitious genetics sequencing projects through the Regeneron Genetics Center®. These efforts underscore Regeneron's commitment to enhancing and expediting the drug development process, positioning it as a leader in the biotechnology sector.

Summarized from source with an LLMView SourceSector: Technology